非酒精性脂肪性肝病患者肠道菌群与胰高血糖素样肽1的相关性分析

刘志平; 赵致维; 张金华

doi:10.3969/j.issn.1001-5256.2020.01.030

非酒精性脂肪性肝病患者肠道菌群与胰高血糖素样肽1的相关性分析

DOI: 10.3969/j.issn.1001-5256.2020.01.030

武汉市汉口医院消化内科

详细信息

中图分类号: R575.5
计量
- 文章访问数: 1095
- HTML全文浏览量: 58
- PDF下载量: 211
- 被引次数: 0
出版历程
- 收稿日期: 2019-07-16
- 出版日期: 2020-01-20

Correlation of intestinal flora with serum glucagon-like peptide-1 level in patients with nonalcoholic fatty liver disease

Department of Gastroenterology,Wuhan Hankou Hospital

摘要

摘要: 目的探讨非酒精性脂肪性肝病（NAFLD）患者肠道菌群失调与血清胰高血糖素样肽（GLP） 1水平的相关性。方法选取2018年1月-2018年12月在武汉市汉口医院就诊的NAFLD患者116例为NAFLD组,另选取同期在本院体检的96例健康者为对照组。收集所有患者的新鲜粪便标本进行细菌培养,分析肠道菌群变化,评估肠道菌群定植抗力（B/E比值）。比较2组之间BMI、甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、空腹血糖（FPG）、空腹胰岛素（FINS）、胰岛素抵抗指数（HOMA-IR）、血清GLP-1水平、肠道菌群的数量及B/E比值的变化。计量资料2组间比较采用t检验;计数资料2组间比较采用χ2检验;相关性分析采用Pearson相关分析和偏相关分析。结果 NAFLD组BMI[（24. 76±2. 93） kg/m2vs （22. 35±2. 54） kg/m2]、TG[（1. 15±0. 65） mmol/L vs （0. 93±0. 62） mmol/L]、TC[（4. 06±1. 02） mmol/L vs ...
- 非酒精性脂肪性肝病 /
- 胃肠道微生物组 /
- 胰高血糖素样肽1
Abstract: Objective To investigate the correlation of intestinal dysbacteriosis with serum glucagon-like peptide-1(GLP-1) level in patients with nonalcoholic fatty liver disease(NAFLD). Methods A total of 116 patients with NAFLD who attended Wuhan Hankou Hospital from January to December 2018,were enrolled as NAFLD group,and 96 healthy individuals who underwent physical examination in our hospital during the same period of time were enrolled as control group. Fresh feces samples were collected from all subjects and bacterial culture was performed; the change in intestinal flora was analyzed,and the Bifidobacterium-Escherichia coli(B/E) ratio was calculated to evaluate the colonization resistance of intestinal flora. The two groups were compared in terms of the changes in body mass index(BMI),triglyceride(TG),total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),fasting plasma glucose(FPG),fasting insulin(FINS),Homeostasis Model Assessment of Insulin Resistance(HOMA-IR),serum GLP-1 level,number of intestinal bacteria,and B/E ratio. The t-test was used for comparison of continuous data between two groups,and the chi-square test was used for comparison of categorical data between two groups. Pearson correlation analysis and partial correlation analysis were performed. Results Compared with the control group,the NAFLD group had significantly higher levels of BMI(24. 76 ±2. 93 kg/m2 vs 22. 35 ± 2. 54 kg/m2,t = 6. 327,P < 0. 05),TG(1. 15 ± 0. 65 mmol/L vs 0. 93 ± 0. 62 mmol/L,t = 2. 504,P < 0. 05),TC(4. 06 ± 1. 02 mmol/L vs 3. 71 ± 1. 15 mmol/L,t = 2. 347,P < 0. 05),LDL-C(2. 76 ± 0. 93 mmol/L vs 2. 33 ± 0. 87 mmol/L,t =3. 450,P < 0. 05),FINS(15. 17 ± 7. 39 m IU/L vs 12. 74 ± 6. 81 m IU/L,t = 2. 469,P < 0. 05),HOMA-IR(2. 58 ± 1. 38 vs 2. 14 ±1. 25,t = 2. 411,P < 0. 05),Enterobacter(9. 56 ± 1. 85 log cfu/g vs 8. 38 ± 1. 92 log cfu/g,t = 4. 544,P < 0. 05),Enterococcus(8. 12 ±1. 47 log cfu/g vs 7. 66 ± 1. 54 log cfu/g,t = 2. 219,P < 0. 05),and Staphylococcus(7. 54 ± 1. 22 log cfu/g vs 7. 03 ± 1. 18 log cfu/g,t =3. 075,P < 0. 05),as well as significantly lower levels of serum GLP-1(6. 95 ± 2. 74 pmol/L vs 8. 06 ± 2. 86 pmol/L,t =-2. 878,P <0. 05),Bifidobacterium(8. 87 ± 1. 76 log cfu/g vs 9. 71 ± 1. 86 log cfu/g,t =-3. 371,P < 0. 05),Lactobacillus(8. 31 ± 1. 55 log cfu/g vs 8. 97 ± 1. 57 log cfu/g,t =-3. 068,P < 0. 05),Bacteroides(8. 66 ± 1. 21 log cfu/g vs 9. 23 ± 1. 34 log cfu/g,t =-3. 251,P <0. 05),and B/E ratio(0. 96 ± 0. 17 vs 1. 15 ± 0. 15,t =-8. 539,P < 0. 05). Serum GLP-1 level was positively correlated with B/E ratio(r = 0. 604,P < 0. 05) and was negatively correlated with BMI,TG,TC,LDL-C,and HOMA-IR(r =-0. 551,-0. 424,-0. 386,-0. 445,and-0. 503,all P < 0. 05). After the control for BMI,TG,TC,LDL-C,and HOMA-IR,serum GLP-1 level was still positively correlated with B/E ratio(r = 0. 576,P < 0. 05). Conclusion The reduction in serum GLP-1 level is correlated with intestinal dysbacteriosis in patients with NAFLD.
- non-alcoholic fatty liver disease /
- gastrointestinal microbiome /
- glucagon-like peptide 1

HTML全文

参考文献(16)

[1] BYRNE CD,TARGHER G. NAFLD:A multisystem disease[J]. J Hepatol,2015,62(S1):s47-s64.

[2] DUTOUR A,ABDESSELAM I,ANCEL P,et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes:A prospective randomized clinical trial using magnetic resonance imaging and spectroscopy[J]. Diabetes Obes Metab,2016,18(9):882-891.

[3] PANG BY,KUANG HY. Research progress of incretin-based therapies on nonalcoholic fatty liver disease[J]. China Med Herald,2018,15(6):28-30,34.(in Chinese)庞宝莹，匡洪宇．肠促胰素类药物治疗非酒精性脂肪性肝病研究进展[J]．中国医药导报，2018,15(6):28-30,34.

[4] GAO H,ZENG Z,ZHANG H. The glucagon-like peptide-1analogue liraglutide inhibits oxidative stress and inflammatory response in the liver of rats with diet-induced non-alcoholic fatty liver disease[J]. Biol Pharm Bull,2015,38(5):694-702.

[5] YANG M,FUKUI H,EDA H,et al. Involvement of gut microbiota in association between GLP-1/GLP-1 receptor expression and gastrointestinal motility[J]. Am J Physiol Gastrointest Liver Physiol,2017,312(4):g367-g373.

[6] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association;Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):947-957.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会．非酒精性脂肪性肝病防治指南(2018年更新版)[J]．临床肝胆病杂志，2018,34(5):947-957.

[7] BOURSIER J,DIEHL AM. Implication of gut microbiota in nonalcoholic fatty liver disease[J]. PLo S Pathog,2015,11(1):e1004559.

[8] SANJOY R,PRAVEEN S,GAIL C. The role of the gut microbiome in nonalcoholic fatty liver disease[J]. Med Sci(Basel),2018,6(2). pii:e47.

[9] BOURSIER J,MUELLER O,BARRET M,et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic functifunction of the gut microbiota[J]. Hepatology,2016,63(3):764-775.

[10] LE ROY T,LLOPIS M,LEPAGE P,et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice[J]. Gut,2013,62(12):1787-1794.

[11] ALISI A,BEDOGNI G,BAVIERA G,et al. Randomised clinical trial:The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis[J]. Aliment Pharmacol Ther,2014,39(11):1276-1285.

[12] WANG W,SHI LP,SHI L,et al. Efficacy of probiotics on the treatment of non-alcoholic fatty liver disease[J]. Chin J Intern Med,2018,57(2):101-106.(in Chinese)王薇，史林平，石蕾，等．肠道益生菌辅助治疗非酒精性脂肪性肝病的临床研究[J]．中华内科杂志，2018,57(2):101-106.

[13] RONVEAUX CC,TOMD,RAYBOULD HE. Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling[J]. J Nutr,2015,145(4):672-680.

[14] HOU HT,QIU YM,ZHANG J,et al. GLP-1 down-regulates mRNA expression of SOCS-3 and SREBP-1c in rats with nonalcoholic fatty liver disease[J]. Chin J Pathophysiology,2016,32(7):1312-1316.(in Chinese)侯洪涛，裘艳梅，张建，等．GLP-1下调非酒精性脂肪肝大鼠SOCS-3和SREBP-1c的表达[J]．中国病理生理杂志，2016,32(7):1312-1316.

[15] LIN CM,LIN WH,ZHOU R,et al. The research progresses on GLP-1 related signal pathways in alleviating non-alcoholic fatty liver disease[J]. Int J Endocrinol Metab,2018,38(3):179-182.(in Chinese)林楚曼，林伟浩，周蕊，等．GLP-1缓解非酒精性脂肪性肝病相关信号通路的研究进展[J]．国际内分泌代谢杂志，2018,38(3):179-182.

[16] YAMANE S,INAGAKI N. Regulation of glucagon-like peptide-1 sensitivity by gut microbiota dysbiosis[J]. J Diabetes Investig,2018,9(2):262-264.

施引文献

资源附件(0)

访问统计